Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Advances in immunotherapy and targeted therapy have transformed non-small cell lung cancer (NSCLC) treatment.
• Limited biomarkers currently exist to guide personalized treatment selection for NSCLC patients.
• Genomic profiling generates crucial clinicogenomic data, enabling the development of mutational biomarkers for predicting drug response.

Purpose of the Study:

• To identify somatic mutation signatures associated with treatment response in non-small cell lung cancer (NSCLC).
• To develop predictive biomarkers for immunotherapy and chemotherapy in NSCLC.
• To create an EGFR wild-type specific mutation signature for optimizing chemotherapy selection.

Main Methods:

• Analysis of the NSCLC GENIE BPC cohort, comprising 2,004 tumor samples from 1,846 patients.
• Identification of somatic mutation signatures linked to immunotherapy and specific chemotherapy regimens (carboplatin, cisplatin, pemetrexed, docetaxel).
• Evaluation of the impact of epidermal growth factor receptor (EGFR) mutation status on the predictive power of chemotherapy-associated signatures.

Main Results:

• Somatic mutation signatures associated with response to immunotherapy and chemotherapy were identified.
• The predictive accuracy of the chemotherapy signature was significantly influenced by EGFR mutation status.
• An EGFR wild-type specific mutation signature was developed for enhanced chemotherapy selection.

Conclusions:

• Developed treatment-specific gene signatures can aid clinicians and patients in choosing optimal therapies.
• These signatures contribute to personalized treatment strategies for non-small cell lung cancer (NSCLC).
• The findings support the use of genomic biomarkers for guiding NSCLC treatment decisions.